Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations

Researchers at the Amsterdam University Medical Center (Amsterdam UMC) have uncovered compelling evidence linking specific gut bacteria to long-term cardiovascular health. Published in the journal npj Biofilms and Microbiomes in early March 2026, their latest study demonstrates that the baseline gut microbiota composition can serve as a highly accurate predictor for future cardiometabolic conditions.

Medical professionals have long recognized the gut microbiome as a crucial factor in human digestion and basic immunity. Still, scientists are now proving its direct and profound influence on systemic diseases. The investigators analyzed extensive sequencing data to pinpoint which bacterial strains confer protective benefits and which increase the risk of major adverse cardiovascular events (MACE). This breakthrough provides a new framework for understanding heart disease and metabolic disorders, enabling early intervention in patients with elevated risk profiles by understanding the complex bacterial ecosystem residing within the human digestive tract.

The HELIUS Study Framework and Multi-ethnic Demographics 

To capture a precise picture of disease development across different populations, the research team utilized data from the HEalthy Life In an Urban Setting (HELIUS) study. As a collaborative project between Amsterdam UMC and the Public Health Service of Amsterdam (GGD Amsterdam), HELIUS is a prospective, population-based cohort study conducted in Amsterdam to investigate cardiovascular diseases, infectious diseases, and mental health conditions such as depression. 

The baseline cohort of the study includes nearly 25,000 participants of Dutch, Surinamese (both African and South Asian), Turkish, Moroccan, and Ghanaian origin. The first four are the largest population groups in Amsterdam, while Ghanaians were chosen because they constitute a rapidly expanding group in the capital of the Netherlands. Additionally, some previous studies have shown that Ghanaians have a significantly higher prevalence of certain cardiometabolic conditions such as hypertension, obesity and type 2 diabetes compared to the Dutch and other ethnic groups.

By studying these diverse demographics, scientists can gain valuable insight into the unequal burden of disease and identify targeted preventive strategies for vulnerable populations. For the current cardiometabolic investigation, researchers analyzed baseline fecal samples from 4,792 HELIUS participants using advanced 16S rRNA sequencing. The team then followed these individuals for an average of 6.2 years (maximum 9.5 years). By linking the microbiome data to hospital and mortality registries, the scientists successfully tracked the long-term incidence of major adverse cardiovascular events and other metabolic conditions.

Tracking Disease Incidence Across Diverse Populations

The longitudinal tracking revealed substantial progression of cardiometabolic disease in the cohort over the follow-up period. The researchers documented 376 new-onset hypertension cases, which accounted for roughly 21% of the at-risk population. The data also showed 375 new cases of dyslipidemia (19%) and 183 new diabetes cases (5.8%). Regarding severe cardiovascular outcomes, 129 participants experienced a MACE, representing 2.7% of the group. Additionally, 180 participants experienced MACE+ events, which equate to 3.8% of the cohort and include broader diagnoses such as angina pectoris, arrhythmia and heart failure.

The study uncovered distinct ethnic variations regarding these severe health outcomes. MACE and MACE+ events occurred most frequently among the South Asian Surinamese participants. However, the statistical associations between specific gut microbiome profiles and the MACE incidence appeared strongest within the Dutch and African Surinamese groups. These figures emphasize the need to include diverse racial and ethnic groups in biopharma research to fully understand how microbial communities interact across genetic and environmental backgrounds.

Identifying Protective Gut Microbes and Harmful Bacterial Strains

The detailed microbial analysis identified several specific bacterial taxa associated with either increased risk or protection against cardiometabolic diseases. An increased abundance of Akkermansia muciniphila and the broader Lachnospiraceae family correlated with a significantly lower risk of adverse cardiovascular events, with Lachnospiraceae demonstrating a protective hazard ratio of 0.84 (a 16% lower risk). Also, specific members of this family such as the Eubacterium xylanophilum group remained significantly protective even after full statistical adjustment, positioning this organism as a strong candidate for future therapeutic investigation.

Conversely, the Ruminococcus gnavus group species demonstrated a clear association with increased risk in the expanded cardiovascular endpoint analyses. Participants who developed diabetes, dyslipidemia, or hypertension generally exhibited slightly lower microbial diversity. The researchers pinpointed Flavonifractor plautii and Ruminococcus gnavus as significant risk factors for metabolic conditions. The former increased the odds for diabetes by a factor of 1.18 and dyslipidemia by 1.14. At the same time, the latter led to a 13% increase in the odds for diabetes and a 12% higher odds for dyslipidemia. 

Moreover, Streptococcus species, Flavonifractor plautii, and Ruminococcus gnavus showed associations with an increased likelihood of developing hypertension. These precise odds ratios provide biopharma developers with concrete microbial targets for diagnostic and therapeutic applications. 

Interestingly, the data also revealed a mild association between the broadly beneficial genus Bifidobacterium and a slightly elevated risk of hypertension (OR 1.06, a 6% increase). While seemingly contradictory, this anomaly underscores the highly complex, context-dependent nature of the human microbiome. Within these intricate ecosystems, the role of certain bacteria can shift in response to the presence of other microorganisms, undiagnosed metabolic stress, or dietary interventions.

Metabolomic Insights and Dietary Interactions

To understand the functional mechanisms behind these microbial associations, the Dutch investigators integrated exploratory metabolomic analyses into their study. They discovered that risk-associated microbes actively influence circulating metabolites in the human bloodstream. Specifically, the analysis linked the harmful Ruminococcus gnavus group species to elevated levels of bile acids and acylcarnitine-related metabolites, which often correlate with metabolic dysfunction and cardiovascular stress. 

On the protective side, beneficial taxa strongly correlated with plant-derived microbial compounds. The team detected elevated levels of xenobiotics such as 3-phenylpropionate, cinnamoylglycine, and enterolactone sulfate in individuals harboring protective gut bacteria. These specific metabolites likely reflect the active microbial metabolism of plant-derived dietary compounds, underscoring the critical interactions between diet and the microbiome in fostering cardiovascular protection. These biochemical insights suggest that the microbiome does not merely exist as a passive marker of health but actively produces compounds that either damage or protect the cardiovascular system over time.

Translating Discoveries into Preventive Clinical Treatments

Overall, the findings from Amsterdam UMC demonstrate that gut microbiome composition serves as a valid longitudinal predictor of cardiometabolic diseases. While the researchers note that current microbiota profiling holds limited diagnostic value on its own, the identified microbial networks show immense promise as potential targets for early preventive measures. Future interventions might include precision prebiotics, targeted probiotics, or refined fecal microbiota transplants designed to cultivate protective species such as Eubacterium xylanophilum while suppressing harmful strains like Ruminococcus gnavus.

By recognizing the intricate connections among intestinal bacteria, metabolites, and multi-ethnic health outcomes, the medical community moves one step closer to personalized microbiome-based strategies to effectively combat the global burden of cardiovascular and metabolic diseases. These ongoing research efforts will ultimately pave the way for innovative treatments tailored to diverse populations worldwide.

Author

Richard Chau